Cardiovascular News

Giving intravenous iron to patients with anaemia before heart surgery reduces the need for a red blood transfusion and results in an extra day at home in the first 90 days after surgery, results of a clinical trial published in the British Medical Journal (BMJ) have shown. This was the headline finding of the ITACS—intravenous […] The post Iron transfusion prior to cardiac surgery reduces the nee…

New randomised trial data support the use of cold-stored platelets to treat active bleeding during cardiac surgery, potentially helping to increase platelet shelf-life and widen accessibility for transfusions, investigators say. “Our findings could result in major international public health benefits,” said Philip Spinella (University of Pittsburgh, Pittsburgh, USA), lead author of the CHIPS stud…

The size of a person’s midsection is a better indicator of cardiovascular disease risk when compared to their body mass index (BMI) alone, according to a study published in the Journal of the American College of Cardiology (JACC). BMI has traditionally been used to determine overweight or obesity, common risk factors for heart disease, but […] The post Study suggests alternatives to BMI for predi…

Jupiter Endovascular today announced the appointment of interventional cardiologist Catalin Toma as chief medical officer. The company have detailed that Toma brings extensive clinical and research experience across the structural heart and interventional landscape to his new role. He serves concomitantly as director of Interventional Cardiology for the UPMC Heart and Vascular Institute in Pittsb…

Versa Vascular, developer of a novel transcatheter tricuspid valve repair system—AdapTR—has announced changes to its senior management team and the completion of new investment to support clinical study of its device. The company announced that Bill Shields, a former vice president and general manager of Medtronic’s Transcatheter Mitral and Tricuspid Therapies division joins as CEO, […] The post …

David Taggart, professor of cardiovascular surgery at the University of Oxford (Oxford, UK), a distinguished academic, clinical investigator and cardiac surgeon, died on 9 August 2026.  Colleagues at the John Radcliffe Hospital in Oxford, UK, where Taggart had practiced as consultant cardiothoracic surgeon since 1995, paid tribute to his legacy as “an outstanding surgeon, a supportive colleague a…

Australian medical robotics company Vexev has announced it has raised US$6 million in new funding to accelerate the path to US Food and Drug Administration (FDA) 510(k) clearance and US commercialisation of VxWave, its robotic tomographic ultrasound platform, designed to improve access to standardised vascular imaging. Vexev’s total funding to date exceeds US$19 million. VxWave […] The post Vexev…

P&F Products & Features has announced the acquisition of AVVie, developer of the AngelValve augmentation system for the treatment of mitral valve disease. AVVie was founded by the cardiac surgeon Werner Mohl (Medical University of Vienna, Vienna, Austria) and spun out of MedUni Vienna. Its technology, also described as the mitral butterfly system, is a […] The post Developer of mitral butterfly s…

AngioInsight has announced the enrolment of the first patient in the SMARTFLOW clinical study, assessing AngioAI+, the company’s investigational software platform designed to assess coronary physiology from routine coronary angiographic images. The prospective, multicentre SMARTFLOW study is co-led by Carlos Collet, director of cardiovascular imaging, physiology and translation therapeutics at th…

Abbott has announced the completion of enrolment in the TECTONIC CAD IVL investigational device exemption (IDE) study, a pivotal trial evaluating the safety and effectiveness of the company’s SonicForce coronary intravascular lithotripsy (IVL) system in patients with severely calcified, de novo coronary lesions prior to stent placement. The TECTONIC CAD IVL trial enrolled 335 patients […] The pos…

Haemonetics Corporation has announced the publication of a study in the open-access journal Heart Rhythm O2 providing new evidence supporting the safety and efficacy of its Vascade MVP XL venous vascular closure system in large-bore sheath procedures. The retrospective cohort study represents the largest reported cohort using the VASCADE MVP XL system to date, Haemonetics […] The post New data av…

Caristo Diagnostics has announced that the US Food and Drug Administration (FDA) has granted de novo authorisation for its CaRi-Heart technology for the quantification of coronary inflammation from routine coronary CT angiography (CCTA). CaRi-Heart unmasks previously hidden inflammation and provides clinicians with actionable insights, enabling earlier intervention and personalised treatments for…

Abbott has initiated the TREAT TR post-market study of the TriClip transcatheter edge-to-edge repair (TEER) system for the treatment of tricuspid regurgitation (TR). The study is designed to evaluate the safety and performance of TriClip in a real-world setting and build on existing evidence concerning the safety and efficacy of the device in addressing TR. […] The post TriClip patients to be fol…

B Braun has announced the enrolment of the first patient in the BASKET BALL trial, an international, randomised, multicentre, open-label trial in patients with coronary artery disease and increased clinical or anatomical risk. The trial is designed to create clinical evidence for a sirolimus-coated balloon—SeQuent SCB—in complex coronary artery disease. The hypothesis of BASKET BALL […] The post …

CroíValve, developer of the Duo transcatheter tricuspid coaptation valve system, has announced the appointment of Jaime Wheeler as CEO, replacing Lucy O’Keeffe in the role who will become the company’s chief operating officer. Wheeler brings more than 25 years of experience having previously served as the senior vice president of global clinical affairs for transcatheter […] The post Edwards Life…

Humacyte has announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of the coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG). Humacyte plans to initiate a phase 2a study of the CTEV in CABG patients during the current quarter. […] The post Coronary tissue engineered v…

Thrombolytic Science has announced that the Turkish Ministry of Health, through the Turkish Medicines and Medical Devices Agency (TİTCK), has authorised the initiation of PROMPT-STEMI, a phase 2 clinical trial evaluating its mutant prourokinase (mproUK)-based sequential fibrinolytic approach in patients with ST-segment elevation myocardial infarction (STEMI). The study is sponsored by TSI Türkiye…

Positive results have been reported from a trial of siRNA—small interfering RNA—therapy targeting coagulation factor XI (FXI) in patients with chronic coronary artery disease. The randomised, double-blind, placebo-controlled European Phase 2a study assessing vortosiran (Ribocure Pharmaceuticals) involved patients with chronic coronary artery disease with previous myocardial infarction (MI) receiv…

Venus Medtech has announced that patient enrolment has been completed in its confirmatory clinical trial for the Venus-PowerX transcatheter aortic valve implantation (TAVI) system. The Venus-PowerX PREVAILS study is a prospective, multicentre, single-arm, objective‑performance‑criterion trial designed to evaluate the safety, efficacy, and device performance of the Venus-PowerX system in patients …